Besponsa
(inotuzumab ozogamicin)Phase 3Antibody–drug conjugate
Inotuzumab ozogamicin is used to treat a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). It works by delivering a toxic compound directly to cancer cells to destroy them.[1] Besponsa is currently being investigated across 12 indications[3], with its most advanced program in Phase 3.[1]
Besponsa is one of 220 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 3.
12
Indications
53
Total Trials
22
Active Trials
219
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Besponsa
WWyeth-Lederle Vaccines
Phase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia11 trials
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06427330·21 enrolled
Show 8 more trials
Lymphoma9 trials
Show 6 more trials
Leukemia7 trials
Show 4 more trials
B-cell acute lymphoblastic leukemia3 trials
B Acute Lymphoblastic Leukemia3 trials
17 more indications
Treatment2 trials
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Not yet recruiting·—·Phase 3·NCT07476729·750 enrolled
B-ALL2 trials
Venetoclax Plus Inotuzumab for B-ALL
Active, not recruiting·—·Phase 1·NCT05016947·23 enrolled
Chemotherapy1 trial
BOS1 trial
Lymphoid Malignancies1 trial
Efficacy and Safety1 trial
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06387121·53 enrolled
Blinatumomab1 trial
Combination Therapy1 trial
Non-Hodgkins Lymphoma1 trial
Minimal Residual Disease1 trial
Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05456698·31 enrolled
Acute Leukemia1 trial
Relapsed/Refractory B-cell ALL1 trial
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial
Regulatory
FDA Approval Timeline[4]
Aug 17, 2017
BESPONSA
BLA BLA761040
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for inotuzumab ozogamicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- CD22 Binding Agent[2]
- Modality
- Antibody–drug conjugate[2]
- Highest Phase
- Phase 3[1]
- Company
- WWyeth-Lederle Vaccines